ArticlePloS one2026
Reducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- O-GlcNAcylation at the tumor-immune interface: a metabolic post-translational code driving immune evasion and therapy resistance in cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
O-GlcNAcylation, a single attachment of N-acetylglucosamine (GlcNAc) on serine/threonine residues of nuclear-cytoplasmic proteins, is frequently upregulated in various cancers and implicated in several aspects of tumor progression. Growing evidence reports that treatments of chemotherapeutic drugs may activate protein O-GlcNAcylation. However, its precise role in modulating chemotherapeutic responses, particularly in colorectal cancer (CRC), remains poorly defined. Herein, we investigate the biological effects of oxaliplatin (OXA), a first-line chemotherapy drug for patients with metastatic CRC, and protein O-GlcNAcylation reduction in SW620 metastatic CRC cells. OXA treatment alone reduced cell viability as well as proliferation, and increased the levels of protein O-GlcNAcylation and GFPT1, the rate limiting enzyme of hexosamine biosynthetic pathway which is a nutrient sensor of glucose metabolism. Inhibition of protein O-GlcNAcylation via genetic knockdown of O-GlcNAc transferase (OGT) or chemical inhibition (OSMI-1) markedly enhanced SW620 sensitive to OXA. This was evidenced by decreased cell viability and proliferation, increased cell apoptosis, and cell cycle arrest. Mass spectrometry-based proteomics and bioinformatics analysis revealed that the combination of OGT knockdown and OXA treatment majorly downregulated several ribosomal proteins. In addition, OXA treatment and OGT knockdown altered proteins involved in critical pathways including DNA synthesome complex, glycolytic process, negative regulation of gene expression, cell cycle process, and negative regulation of protein phosphorylation. Specifically, OGT downregulated several ribosomal proteins, and OGT knockdown influenced proteins across the identified pathways. Taken together, these findings demonstrate that reducing OGT and protein O-GlcNAcylation may enhance the sensitivity of CRC cells to OXA, and the altered pathways may offer new insights into potential mechanisms for overcoming CRC chemoresistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.